Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy

Purpose: Primary central nervous system lymphoma (PCNSL) is a rare type of extra-nodal non-Hodgkin lymphoma, but the prognostic value of blood parameters indicating systemic inflammation and nutritional status remains unknown. We aim to explore the prognostic role of blood parameters in PCNSL.Method...

Full description

Bibliographic Details
Main Authors: Qian Luo, Chunli Yang, Chunxi Fu, Wanchun Wu, Yi Wei, Liqun Zou
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.639644/full
id doaj-c364afe192234234af1ca39db4a5ef78
record_format Article
spelling doaj-c364afe192234234af1ca39db4a5ef782021-04-29T11:24:19ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-04-011110.3389/fonc.2021.639644639644Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based TherapyQian Luo0Chunli Yang1Chunxi Fu2Wanchun Wu3Yi Wei4Liqun Zou5Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Central Medical Transportation, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, ChinaPurpose: Primary central nervous system lymphoma (PCNSL) is a rare type of extra-nodal non-Hodgkin lymphoma, but the prognostic value of blood parameters indicating systemic inflammation and nutritional status remains unknown. We aim to explore the prognostic role of blood parameters in PCNSL.Methods: All PCNSL patients diagnosed at West China Hospital between February 2011 and February 2020 were retrospectively screened. For patients who were initially treated with high-dose methotrexate (HD-MTX)-based therapy, clinical data were collected. Survival analyses were performed using the Kaplan–Meier method and multivariable Cox proportional regression. The accuracies of different multivariate models were assessed by Harrell's C statistical analysis (C-index).Results: Sixty patients were included. Median overall survival (OS) was 4.8 ± 3.7 years, and median progression-free survival (PFS) was 1.9 ± 1.3 years. In the multivariate analysis, hemoglobin (Hb) (HR 3.940, p = 0.013), neutrophil–lymphocyte ratio (NLR) (HR 10.548, p = 0.034), and total bilirubin (TBIL) (HR 3.429, p = 0.004) had independent prognostic values for PFS, while lymphocyte–monocyte ratio (LMR) (HR 6.195, p = 0.039), systemic immune-inflammation index (SII) (HR 5.144, p = 0.012), and TBIL (HR 3.892, p = 0.009) were independently related to OS. The C-index of the Memorial Sloan-Kettering Cancer Center (MSKCC) score increased from 0.57 to 0.72 when SII and TBIL were combined.Conclusions: Our study indicated that pretreatment Hb, NLR, SII, LMR, and TBIL were convenient prognostic factors in PCNSL. Adding SII and TBIL to the MSKCC score can better predict the survival of PCNSL based on HD-MTX regimens.https://www.frontiersin.org/articles/10.3389/fonc.2021.639644/fullprimary central nervous system lymphomaprognosisblood markerC-indexMSKCC
collection DOAJ
language English
format Article
sources DOAJ
author Qian Luo
Chunli Yang
Chunxi Fu
Wanchun Wu
Yi Wei
Liqun Zou
spellingShingle Qian Luo
Chunli Yang
Chunxi Fu
Wanchun Wu
Yi Wei
Liqun Zou
Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy
Frontiers in Oncology
primary central nervous system lymphoma
prognosis
blood marker
C-index
MSKCC
author_facet Qian Luo
Chunli Yang
Chunxi Fu
Wanchun Wu
Yi Wei
Liqun Zou
author_sort Qian Luo
title Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy
title_short Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy
title_full Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy
title_fullStr Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy
title_full_unstemmed Prognostic Role of Blood Markers in Primary Central Nervous System Lymphoma Patients Treated With High-Dose Methotrexate-Based Therapy
title_sort prognostic role of blood markers in primary central nervous system lymphoma patients treated with high-dose methotrexate-based therapy
publisher Frontiers Media S.A.
series Frontiers in Oncology
issn 2234-943X
publishDate 2021-04-01
description Purpose: Primary central nervous system lymphoma (PCNSL) is a rare type of extra-nodal non-Hodgkin lymphoma, but the prognostic value of blood parameters indicating systemic inflammation and nutritional status remains unknown. We aim to explore the prognostic role of blood parameters in PCNSL.Methods: All PCNSL patients diagnosed at West China Hospital between February 2011 and February 2020 were retrospectively screened. For patients who were initially treated with high-dose methotrexate (HD-MTX)-based therapy, clinical data were collected. Survival analyses were performed using the Kaplan–Meier method and multivariable Cox proportional regression. The accuracies of different multivariate models were assessed by Harrell's C statistical analysis (C-index).Results: Sixty patients were included. Median overall survival (OS) was 4.8 ± 3.7 years, and median progression-free survival (PFS) was 1.9 ± 1.3 years. In the multivariate analysis, hemoglobin (Hb) (HR 3.940, p = 0.013), neutrophil–lymphocyte ratio (NLR) (HR 10.548, p = 0.034), and total bilirubin (TBIL) (HR 3.429, p = 0.004) had independent prognostic values for PFS, while lymphocyte–monocyte ratio (LMR) (HR 6.195, p = 0.039), systemic immune-inflammation index (SII) (HR 5.144, p = 0.012), and TBIL (HR 3.892, p = 0.009) were independently related to OS. The C-index of the Memorial Sloan-Kettering Cancer Center (MSKCC) score increased from 0.57 to 0.72 when SII and TBIL were combined.Conclusions: Our study indicated that pretreatment Hb, NLR, SII, LMR, and TBIL were convenient prognostic factors in PCNSL. Adding SII and TBIL to the MSKCC score can better predict the survival of PCNSL based on HD-MTX regimens.
topic primary central nervous system lymphoma
prognosis
blood marker
C-index
MSKCC
url https://www.frontiersin.org/articles/10.3389/fonc.2021.639644/full
work_keys_str_mv AT qianluo prognosticroleofbloodmarkersinprimarycentralnervoussystemlymphomapatientstreatedwithhighdosemethotrexatebasedtherapy
AT chunliyang prognosticroleofbloodmarkersinprimarycentralnervoussystemlymphomapatientstreatedwithhighdosemethotrexatebasedtherapy
AT chunxifu prognosticroleofbloodmarkersinprimarycentralnervoussystemlymphomapatientstreatedwithhighdosemethotrexatebasedtherapy
AT wanchunwu prognosticroleofbloodmarkersinprimarycentralnervoussystemlymphomapatientstreatedwithhighdosemethotrexatebasedtherapy
AT yiwei prognosticroleofbloodmarkersinprimarycentralnervoussystemlymphomapatientstreatedwithhighdosemethotrexatebasedtherapy
AT liqunzou prognosticroleofbloodmarkersinprimarycentralnervoussystemlymphomapatientstreatedwithhighdosemethotrexatebasedtherapy
_version_ 1721501320771272704